Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced Aug. 21, 2026, that the first patient has been enrolled in the ReVeRA-301 Phase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE